BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
52.00
+0.51 (0.99%)
Sep 17, 2025, 9:00 AM EDT - Market open
BridgeBio Pharma Employees
BridgeBio Pharma had 730 employees as of December 31, 2024. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
n/a
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 730 | 174 | 31.29% |
Dec 31, 2023 | 556 | 160 | 40.40% |
Dec 31, 2022 | 396 | -182 | -31.49% |
Dec 31, 2021 | 578 | 182 | 45.96% |
Dec 31, 2020 | 396 | 148 | 59.68% |
Dec 31, 2019 | 248 | 96 | 63.16% |
Dec 31, 2018 | 152 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BBIO News
- 6 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript) - Seeking Alpha
- 8 days ago - BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 10 days ago - Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism - GlobeNewsWire
- 14 days ago - BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - GlobeNewsWire
- 15 days ago - BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - GlobeNewsWire
- 18 days ago - Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension - GlobeNewsWire
- 21 days ago - BridgeBio to Participate in September Investor Conferences - GlobeNewsWire